Nothing Special   »   [go: up one dir, main page]

AR008389A1 - Derivados peptidicos - Google Patents

Derivados peptidicos

Info

Publication number
AR008389A1
AR008389A1 ARP970102498A ARP970102498A AR008389A1 AR 008389 A1 AR008389 A1 AR 008389A1 AR P970102498 A ARP970102498 A AR P970102498A AR P970102498 A ARP970102498 A AR P970102498A AR 008389 A1 AR008389 A1 AR 008389A1
Authority
AR
Argentina
Prior art keywords
derivatives
peptide derivatives
treatment
pharmaceutical
new peptide
Prior art date
Application number
ARP970102498A
Other languages
English (en)
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9611881.5A external-priority patent/GB9611881D0/en
Priority claimed from GBGB9622890.3A external-priority patent/GB9622890D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of AR008389A1 publication Critical patent/AR008389A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/825Bacteria
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/85Reproductive organs or embryos
    • Y10S530/851Placenta; amniotic fluid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Trata de derivados peptídicos, utiles para uso farmacéutico, de formula (I), P-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-Q, donde P, AA1, AA2, AA3, AA4, AA5,AA6, AA7, AA8 y Q poseen diferentes significados definidos en el presente contexto, y sus sales aceptables para uso farmacéutico, y de composicionesfarmacéuticas que contienen dichos derivados. Los nuevos derivados peptídicos son valiosos para el tratamiento de enfermedades inflamatorias o autoinmunesmediadas por células T dependientes delMHC clase II, tal como la artritis reumatoidea. Trata, además, de los procesos para la elaboracion de los nuevosderivados peptídicos y del uso de los compuestos en el tratamiento clínico.
ARP970102498A 1996-06-07 1997-06-06 Derivados peptidicos AR008389A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9611881.5A GB9611881D0 (en) 1996-06-07 1996-06-07 Peptide derivatives
GBGB9622890.3A GB9622890D0 (en) 1996-11-02 1996-11-02 Peptide compounds

Publications (1)

Publication Number Publication Date
AR008389A1 true AR008389A1 (es) 2000-01-19

Family

ID=26309459

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102498A AR008389A1 (es) 1996-06-07 1997-06-06 Derivados peptidicos

Country Status (21)

Country Link
US (2) US6541453B2 (es)
EP (1) EP0914333B1 (es)
JP (1) JP2000512277A (es)
KR (1) KR100451522B1 (es)
CN (1) CN1130372C (es)
AR (1) AR008389A1 (es)
AT (1) ATE283278T1 (es)
AU (1) AU727757B2 (es)
BR (1) BR9709533A (es)
CA (1) CA2252417A1 (es)
DE (1) DE69731747T2 (es)
HR (1) HRP970308B1 (es)
ID (1) ID17440A (es)
IL (1) IL127332A0 (es)
NO (1) NO985680L (es)
NZ (1) NZ332347A (es)
PL (1) PL330348A1 (es)
SK (1) SK166798A3 (es)
TR (1) TR199802537T2 (es)
TW (1) TW474947B (es)
WO (1) WO1997046578A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9809021D0 (en) * 1998-04-29 1998-06-24 Zeneca Ltd Chemical process
KR20020047245A (ko) * 1999-10-18 2002-06-21 에프.지.엠. 헤르만스 ; 이.에이치. 리링크 면역요법에 사용하기 위한 수정 펩티드 및 펩티드모방체
JP2008188285A (ja) * 2007-02-06 2008-08-21 Bridgestone Corp バックパッド及び車両用シート
CN102186883B (zh) * 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
AU2011215704B2 (en) 2010-02-11 2015-07-23 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도
SG11201505860XA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
US9738650B2 (en) 2013-01-29 2017-08-22 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EP2951182B1 (en) 2013-01-29 2020-03-18 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP2016506962A (ja) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系nmda受容体モジュレーターおよびその使用
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
CA3031539C (en) 2016-08-01 2023-11-28 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
ES2979128T3 (es) 2016-08-01 2024-09-24 Tenacia Biotechnology Hong Kong Co Ltd Moduladores del receptor NMDA espirolactama y bis-espirolactama y uso de los mismos
SG10202101055VA (en) 2016-08-01 2021-03-30 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
CA3089561A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109115899A (zh) * 2018-06-19 2019-01-01 南京肽业生物科技有限公司 一种Fmoc氨基酸的分析方法
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
EP4141110A1 (en) 2020-04-24 2023-03-01 Obshchestvo S Ogranichennoy Otvetstvennost'yu "Ingenik" Method for producing particles of bacteriophages of the genus levivirus

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254107A (en) 1979-11-27 1981-03-03 Merck & Co., Inc. Long-lasting agonists of enkephalin
US4301151A (en) 1979-11-27 1981-11-17 Merck & Co., Inc. Long-lasting agonists of enkephalin
US4474778A (en) 1983-11-09 1984-10-02 E. R. Squibb & Sons, Inc. Lactam containing compounds, their pharmaceutical compositions and method of use
US4680283A (en) 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
DE3711335A1 (de) 1987-04-03 1988-10-20 Merck Patent Gmbh Aminosaeurederivate
US5331089A (en) 1988-03-25 1994-07-19 Merck Sharpe & Dohme, Ltd. Peptides useful as tachykinin agonists
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
WO1990003399A1 (en) * 1988-09-30 1990-04-05 Australian Commercial Research & Development Limited Amino acid transport proteins, amino acid analogues, assay apparatus, uses thereof for treatment and diagnosis of cancer
US5223485A (en) 1989-01-31 1993-06-29 Abbott Laboratories Anaphylatoxin-receptor ligands
AU8305491A (en) 1990-08-01 1992-03-02 Cytel Corporation Novel immunosuppressant peptides
DE4034829A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh Cyclopeptide
WO1993005011A1 (en) 1991-08-29 1993-03-18 Sandoz Ltd. Novel immunosuppressants
JPH0725887A (ja) 1993-06-04 1995-01-27 Sterling Winthrop Inc インターロイキン−1β転換酵素阻害剤
ATE415173T1 (de) 1993-09-14 2008-12-15 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
WO1995026980A2 (en) * 1994-04-01 1995-10-12 Immulogic Pharmaceutical Corporation Haptenated peptides and uses thereof
ATE206433T1 (de) 1995-03-24 2001-10-15 Molecumetics Ltd Beta-schleifenähnliche verbindungen und deren verwendung als protease-inhibitoren
US5840835A (en) 1995-10-30 1998-11-24 Merck & Co., Inc. Inhibitors of peptide binding to MHC class II proteins
US5719296A (en) 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
US5817757A (en) 1995-10-30 1998-10-06 Merck & Co., Inc. Inhibitors of peptide binding to MHO class II proteins
AU7604196A (en) 1995-10-30 1997-05-22 Merck & Co., Inc. Novel inhibitors of peptide binding to mhc class ii proteins
GB9702377D0 (en) * 1996-02-23 1997-03-26 Zeneca Ltd Peptide derivatives
GB9621836D0 (en) 1996-10-19 1996-12-11 Zeneca Ltd Peptide compounds
GB9625865D0 (en) 1996-12-12 1997-01-29 Zeneca Ltd Peptides

Also Published As

Publication number Publication date
HRP970308A2 (en) 1998-04-30
NZ332347A (en) 2000-05-26
EP0914333B1 (en) 2004-11-24
DE69731747T2 (de) 2006-02-02
CN1130372C (zh) 2003-12-10
KR20000016465A (ko) 2000-03-25
NO985680D0 (no) 1998-12-04
TR199802537T2 (xx) 1999-03-22
ID17440A (id) 1997-12-24
US6541453B2 (en) 2003-04-01
SK166798A3 (en) 1999-07-12
NO985680L (no) 1999-02-04
ATE283278T1 (de) 2004-12-15
DE69731747D1 (de) 2004-12-30
BR9709533A (pt) 1999-08-10
AU2972097A (en) 1998-01-05
TW474947B (en) 2002-02-01
US20020103335A1 (en) 2002-08-01
US20030195158A1 (en) 2003-10-16
EP0914333A1 (en) 1999-05-12
AU727757B2 (en) 2000-12-21
CA2252417A1 (en) 1997-12-11
WO1997046578A1 (en) 1997-12-11
HRP970308B1 (en) 2002-04-30
PL330348A1 (en) 1999-05-10
IL127332A0 (en) 1999-09-22
KR100451522B1 (ko) 2004-12-08
CN1221424A (zh) 1999-06-30
JP2000512277A (ja) 2000-09-19

Similar Documents

Publication Publication Date Title
AR008389A1 (es) Derivados peptidicos
CL2018003348A1 (es) Péptidos y combinación de péptidos y andamiajes novedosos para su uso en inmunoterapia contra carninoma de células renales (rcc) y otros canceres. (divisional solicitud 201702448)
Low et al. Chemical characterization of thymosin beta 4.
ES2193145T3 (es) Proteinas procoagulants quimericas.
CY1109649T1 (el) Αντιγονα και συνθεσεις απο neisseria
ES2190432T3 (es) Activacion in vitro de celulas t citotoxicas.
ES2195664T3 (es) Uso de fumaratos de dialquilo.
AR010348A1 (es) Cetobenzamidas, su utilizacion y composicion farmeceutica que las contienen
AR001288A1 (es) Anticuerpos monoclonales de monos especificos paraB7, 1 Y/O B7,2 humano, sus formas primatizadas, composiciones farmaceuticas con anticuerpos y su uso como inmunosupresores.
CO4600637A1 (es) Compuestos para inmunoterapia e inmunodiagnosis del cancer de prostata
CY1115885T1 (el) Αντιστρεπτα πεγκυλιωμενα (pegylated) φαρμακα
DE69739497D1 (de) Menschlische Telomerase katalytische Untereinheit
UY25246A1 (es) Imidazotriazinonas sustituidas por 2-fenilo
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
ATE286128T1 (de) Conotoxine
GT199900150A (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas.
ATE271058T1 (de) Mycophenol bisphosponatverbindungen
CY1109710T1 (el) Επιτοπα βοηθητικων τ λεμφοκυτταρων
AR041067A1 (es) Formulacion estable de un anticuerpo modificado con el ph optimizado
AR018201A1 (es) Compuesto de mesilato de n-(3-etinilfenil)-6,7-bis-(2-metoxietoxi)-4-quinazolinamina, composiciones que los contienen y su uso de dichos compuestos para la preparacion de medicamentos.
ES2169356T3 (es) Procedimiento para la preparacion de nitrobifenileno.
AR031924A1 (es) Anticuerpos anti-cd28 silenciados y el uso de estos
DE60231986D1 (de) Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose
CU23228A1 (es) Fragmentos de anticuerpos especificos para el antigeno carcinoembrionario humano (cea) secuencias de sus regiones variables y vectores para la expresion microbiana de los mismos
EP0235064A3 (en) Aromatic compounds with amide structure, derivatives of amino-benzoic acids, hydroxybenzoic acids, cinnamic acids, urocanic acids and benzimidazoles, absorbing uvb and/or uva